Skip to main content
Premium Trial:

Request an Annual Quote

Gen-Probe, BioMerieux Pen Three Technology Agreements

NEW YORK, Oct. 7 (GenomeWeb News) - Gen-Probe and BioMerieux have signed three agreements in which Gen-Probe will pay for access to BioMerieux's blood clot-related biomarkers for blood clotting disorders, Gen-Probe will gain negotiation rights for access to the BioMerieux Nuclisens EasyQ platform, and BioMerieux will have access to Gen-Probe's ribosomal RNA markers, said BioMerieux in a statement today.


Gen-Probe will pay $1 million to use the blood clot-related biomarkers "to develop tests that detect mutations in the genes that code for factor V and prothrombin," which are proteins that control the blood clotting process, said the statement.


Under the Nuclisens EasyQ platform arrangement, Gen-Probe may negotiate to "develop TMA amplified assays complementary to bioMerieux product lines" for further distribution by BioMerieux, the statement said.


BioMerieux will pay $250,000 for a limited research license and an option to develop diagnostic products, using Gen-Probe's ribosomal RNA markers, said BioMerieux. If the option is exercised, BioMerieux may as much as $7.5 million, "depending on the number of the targets exercised," the statement said. Under the licenses, Gen-Probe will also receive royalties on the sale of products developed using its technology, the statement added.


The Scan

More Boosters for US

Following US Food and Drug Administration authorization, the Centers for Disease Control and Prevention has endorsed booster doses of the Moderna and Johnson & Johnson SARS-CoV-2 vaccines, the Washington Post writes.

From a Pig

A genetically modified pig kidney was transplanted into a human without triggering an immune response, Reuters reports.

For Privacy's Sake

Wired reports that more US states are passing genetic privacy laws.

Science Paper on How Poaching Drove Evolution in African Elephants

In Science this week: poaching has led to the rapid evolution of tuskless African elephants.